- Home
- LTRN vs RAND Comparison
LTRN vs RAND Comparison
Compare LTRN & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LTRN | RAND |
|---|---|---|
| Founded | 2013 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 34.6M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | LTRN | RAND |
|---|---|---|
| Price | $1.56 | $11.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 3.7K |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 9.89% |
| EPS Growth | ★ 18.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $10.05 |
| 52 Week High | $5.74 | $21.30 |
Technical Indicators
Market Signals| Indicator | LTRN | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 48.74 |
| Support Level | $1.11 | $10.37 |
| Resistance Level | $3.79 | $12.50 |
| Average True Range (ATR) | 0.32 | 0.47 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 35.50 | 65.10 |
Price Performance
Historical ComparisonAbout LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.